⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL28209229 | 1.00 | TSHR (0.80) | — | |
| Hexane SCHEMBL44009 | 0.95 | — | — | |
| Decane SCHEMBL8382473 | 0.90 | TSHR (0.80) | — | |
| Decane SCHEMBL2861344 | 0.90 | TSHR (0.80) | — | |
| Tetradecane SCHEMBL25387874 | 0.89 | TSHR (1.00) | — | |
| SCHEMBL23854647 | 0.89 | TSHR (1.00) | — | |
| SCHEMBL198343 | 0.89 | TSHR (1.00) | — | |
| Decane SCHEMBL23499900 | 0.89 | TSHR (1.00) | — | |
| Heptane SCHEMBL10948326 | 0.89 | TSHR (1.00) | — | |
| Decane SCHEMBL170135 | 0.89 | TSHR (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-2992334-B1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2018-06-27 | — | — | EP | disclosed |
| US-9784701-B2 | Phosphatidylalkanols and compositions thereof | Pethmark AB (SE) | 2017-10-10 | — | — | US | disclosed |
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-20170052132-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2017-02-23 | — | — | US | disclosed |
| US-9499572-B2 | Phosphatidylalkanols and compositions thereof | Pethmark AB (SE) | 2016-11-22 | — | — | US | disclosed |
| US-20160052946-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2016-02-25 | — | — | US | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-1581523-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | disclosed |